In the Pipeline

In the Pipeline

• EntreMed has begun a Phase II clinical trial with its angiogenesis inhibitor Endostatin for the treatment of Stage IV metastatic melanoma. In February, EntreMed’s angiogenesis inhibitor received orphan drug status from the FDA.

• Millennium Pharmaceuticals has announced the initiation of a Phase I clinical trial of MLN518 in patients with acute myeloid leukemia. MLN518 is the first receptor tyrosine kinase (RTK) inhibitor of Millennium’s RTK program to enter human clinical trials.

• Cell Genesys has initiated a Phase II clinical trial of GVAX pancreatic cancer vaccine in patients with inoperable or metastatic pancreatic cancer.

• Medinox has started a Phase I clinical trial of NOX-700, an orally active nitric oxide blocking agent in development for diabetes mellitus.